• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

This product is currently not available for purchase.

RELATED PRODUCTS

Pharmaceuticals in France - Industry and Country Analysis Product Image

Pharmaceuticals in France - Industry and Country Analysis

  • ID: 1865816
  • July 2011
  • Region: France
  • 74 pages
  • Datamonitor

Project Synopsis:
Pharmaceuticals in France – Industry and Country Analysis provides five forces Industry analysis, along with PESTLE country analysis of France. This report concludes with profiles of the leading companies in the French pharmaceuticals market.

Project Description:
Includes market value/volume, geographical segmentation, and five forces (buyer power, supplier power, new entrants, substitutes, and rivalry) analysis of the Pharmaceuticals Industry in France. The PESTLE analysis section analyzes the current challenges, future prospects and risks across political, economic, social, technological, legal and environmental areas of the country.

Scope:
- Contains data on market value, volume and/or segmentation for Pharmaceuticals in France

- Incorporates in-depth five forces competitive environment analysis

- analyzes the political, economic, social, technological, legal and environmental (PESTLE) structure of France

- The leading companies are identified with supporting key financial metrics (where available)

Market Definition:
The pharmaceuticals market consists of ethical drugs only and does not include consumer READ MORE >

EXECUTIVE SUMMARY
INTRODUCTION
Market definition
Research highlights
PHARMACEUTICALS IN FRANCE: MARKET OVERVIEW
Market analysis
Market Value, 2006–10
Market value forecast, 2010–15
Market Segmentation by Category
Market Segmentation by Geography
PHARMACEUTICALS IN FRANCE: FIVE FORCES ANALYSIS
Summary
Buyer power
Supplier power
New entrants
Substitutes
Rivalry
FRANCE: PESTLE ANALYSIS
Summary
Political analysis
Economic analysis
Social analysis
Technology analysis
Legal analysis
Environmental analysis
PHARMACEUTICALS IN FRANCE: LEADING COMPANIES
Market Share
AstraZeneca PLC
GlaxoSmithKline Plc
Pfizer Inc.
APPENDIX
Methodology
ABOUT OUR
Premium Reports
Summary Reports
Datamonitor consulting

LIST OF TABLES
Table 1: France pharmaceuticals market value: $ billion, 2006–10(e)
Table 2: France pharmaceuticals market value forecast: $ billion, 2010–15
Table 3: France pharmaceuticals market segmentation I:% share, by value, 2010(e)
Table 4: France pharmaceuticals market segmentation II: % share, by value, 2010(e)
Table 5: Analysis of France’s political landscape
Table 6: Analysis of France’s economy
Table 7: Analysis of France’s social system
Table 8: Analysis of France’s technology landscape
Table 9: Analysis of France’s legal landscape
Table 10: Analysis of France’s environmental landscape
Table 11: France pharmaceuticals market share: % share, by value, 2010(e)
Table 12: AstraZeneca PLC: key facts
Table 13: AstraZeneca PLC: key financials ($)
Table 14: AstraZeneca PLC: key financial ratios
Table 15: GlaxoSmithKline Plc: key facts
Table 16: GlaxoSmithKline Plc: key financials ($)
Table 17: GlaxoSmithKline Plc: key financials (£)
Table 18: GlaxoSmithKline Plc: key financial ratios
Table 19: Pfizer Inc.: key facts
Table 20: Pfizer Inc.: key financials ($)
Table 21: Pfizer Inc.: key financial ratios

LIST OF FIGURES
Figure 1: France pharmaceuticals market value: $ billion, 2006–10(e)
Figure 2: France pharmaceuticals market value forecast: $ billion, 2010–15
Figure 3: France pharmaceuticals market segmentation I:% share, by value, 2010(e)
Figure 4: France pharmaceuticals market segmentation II: % share, by value, 2010(e)
Figure 5: Forces driving competition in the pharmaceuticals market in France, 2010
Figure 6: Drivers of buyer power in the pharmaceuticals market in France, 2010
Figure 7: Drivers of supplier power in the pharmaceuticals market in France, 2010
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2010
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2010
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in France, 2010
Figure 11: France pharmaceuticals market share: % share, by value, 2010(e)
Figure 12: AstraZeneca PLC: revenues & profitability
Figure 13: AstraZeneca PLC: assets & liabilities
Figure 14: GlaxoSmithKline Plc: revenues & profitability
Figure 15: GlaxoSmithKline Plc: assets & liabilities
Figure 16: Pfizer Inc.: revenues & profitability
Figure 17: Pfizer Inc.: assets & liabilities

Note: Product cover images may vary from those shown

Our Clients

Our clients' logos